AZD1480

DRUG2 trials

Sponsors

AstraZeneca

Conditions

Essential Thrombocythaemia MyelofibrosisPost-Polycythaemia VeraPrimary Myelofibrosis (PMF)Solid Malignancies

Phase 1

Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases

CompletedNCT00910728

AstraZenecaEssential Thrombocythaemia Myelofibrosis, Post-Polycythaemia Vera, Primary Myelofibrosis (PMF)

Start: 2009-05-31End: 2014-08-31Updated: 2017-04-24

Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours

TerminatedNCT01112397

AstraZenecaSolid Malignancies

Start: 2010-04-30End: 2012-09-30Updated: 2013-07-22